{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:26:41Z","timestamp":1781677601285,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.urolonc.2008.10.024","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T05:23:20Z","timestamp":1241501000000},"page":"325-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Optimizing BCG therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Michael A.","family":"O'Donnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2008.10.024_bib1","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 Update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: Significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: Multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Gu\u00e9rin failure pattern on subsequent response to bacille Calmette-Gu\u00e9rin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2008.10.024_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-5347(18)33078-7","article-title":"Low efficacy of intravesical BCG immunotherapy in elderly patients with intermediate-high risk Ta-T1 transitional cell carcinoma of the bladder: Long term experience of a single institution","volume":"175","author":"Verrini","year":"2006","journal-title":"J Urol Suppl"},{"key":"10.1016\/j.urolonc.2008.10.024_bib8","unstructured":"Kohjimoto Y, Iba A, Kuramoto T, et al. Impact of age on outcome of patients with superficial bladder cancer. Proceedings of the Societe' Internationale d'Urologie meeting, Cape Town, South Africa, November 2006."},{"key":"10.1016\/j.urolonc.2008.10.024_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Gu\u00e9rin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2008.10.024_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.eururo.2003.12.016","article-title":"A second-look TUR in T1 transitional cell carcinoma: Why?","volume":"45","author":"Jakse","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","article-title":"Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study","volume":"170","author":"Grimm","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00365590510007793-1","article-title":"Results of second look resection after primary resection of T1 tumour of the urinary bladder","volume":"39","author":"Jahnson","year":"2005","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib13","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","article-title":"Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy","volume":"174","author":"Herr","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","article-title":"Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib15","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin vs. mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2008.10.024_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2008.10.024_bib21","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicenter, randomized prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: Low-dose bacillus Calmette-Guerin (27 mg) vs. very low-dose bacillus Calmette-Guerin (13.5 mg) vs. mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib23","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2008.10.024_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: A solution to side-effects?","volume":"37","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib25","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"Andius","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2008.10.024_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib28","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-\u03b1 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.ju.0000161589.85869.ae","article-title":"Cyclooxygenase-2 inhibition: A potential mechanism for increasing the efficacy of bacillus Calmette-Guerin immunotherapy for bladder cancer","volume":"174","author":"Dovedi","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN- \u03b3 production: Cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.urolonc.2008.10.024_bib31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0167-7799(97)01134-7","article-title":"The genetic reconstruction of BCG as a new immunotherapeutic tool","volume":"15","author":"O'Donnell","year":"1997","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1445-2197.1993.tb00060.x","article-title":"The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guerin efficacy for superficial bladder cancer","volume":"63","author":"P'ng","year":"1993","journal-title":"Aust NZ J Surg"},{"key":"10.1016\/j.urolonc.2008.10.024_bib33","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/S0022-5347(17)39741-0","article-title":"Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors","volume":"144","author":"Hudson","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000474631","article-title":"Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"23","author":"Witjes","year":"1993","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00345-007-0198-z","article-title":"Study on enhancement of fibronectin-mediated bacillus Calmette-Guerin attachment to urinary bladder wall in rabbits","volume":"25","author":"Shen","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib36","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.juro.2007.11.045","article-title":"The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study","volume":"179","author":"Pan","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib37","series-title":"Bladder Tumors","first-page":"189","article-title":"T1 Urothelial Carcinoma of the Bladder","author":"Jewett","year":"2006"},{"key":"10.1016\/j.urolonc.2008.10.024_bib38","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U","article-title":"Survival of patients with carcinoma in situ of the urinary bladder","volume":"85","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2008.10.024_bib39","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","article-title":"Primary superficial bladder cancer risk groups according to progression, mortality and recurrence","volume":"164","author":"Mill\u00e1n-Rodr\u00edguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.10.024_bib40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143908003189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143908003189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:55:59Z","timestamp":1761040559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143908003189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1078143908003189"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.10.024","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing BCG therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}